

90 Park Avenue  
New York NY 10016  
Main 212 336 8000  
Fax 212 336 8001  
Web www.arelaw.com

*Partners*  
Morton Amster  
Jesse Rothstein (1934 - 2003)  
Daniel Ebenstein  
Philip H. Gottfried  
Michael J. Berger  
Neil M. Zipkin  
Anthony F. Lo Cicero  
Kenneth P. George  
Abraham Kasdan, Ph.D.  
Ira E. Silfin  
Chester Rothstein  
Craig J. Arnold  
Kenneth M. Bernstein  
Joseph M. Casino

*Senior Counsel*  
Charles R. Macedo  
Michael V. Solomita  
  
*Associates*  
Patrick Boland\*  
John S. Economou  
Holly Pekowsky  
Michael P. Kenney  
Marion P. Metelski  
Max Vern  
Karl J. Kolbinger

Brian A. Comack  
Richard S. Mandaro  
Marc J. Jason  
Elie H. Gendloff, Ph.D.  
David Mitnick  
Charles W. Rath  
David A. Boag  
Mathieu Hausig  
Jung S. Hahn  
Reiko Kaji  
Alan D. Miller, Ph.D.  
John A. Lepore  
Norajean McCaffrey

Benjamin M. Halpern\*  
Matthew A. Fox  
Michael J. Kasdan  
Rebecca R. Eisenberg  
Stuart Shapley  
Howard Wizenfeld

\*Not admitted in New York

June 20, 2006

Elie H. Gendloff, Ph.D., Esq.  
Direct 212 336 8108  
E-mail egendlof@arelaw.com

Via Express Mail  
(EV 800501746 US)

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing label No.	EV 800501746 US
Date of Deposit:	June 20, 2006
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Elie H. Gendloff
Signature:	

Re: U.S. Utility Patent Application No. 10/624,080  
Title: INHIBITION OF HIV-1 VIRION PRODUCTION BY  
A TRANSDOMINANT MUTANT OF INTEGRASE  
INTERACTOR 1 (INI1)/Hsnf  
Inventor: Ganjam V. Kalpana  
Our Files: 96700/819

Dear Sir:

Pursuant to our receipt of an Election/Restriction requirement under 35 U.S.C. 121 dated May 24, 2006 in connection with the above-identified application, enclosed please find the following documents for filing a reply in the name of Ganjam V. Kalpana, entitled INHIBITION OF HIV-1 VIRION PRODUCTION BY A TRANSDOMINANT MUTANT OF INTEGRASE INTERACTOR 1 (INI1)/Hsnf, comprising the following:

1. a "Reply to Election/Restriction" (2 pages); and
2. a return receipt postcard.

Commissioner for Patents  
Alexandria, VA 22313-1450  
Mail Stop Amendment  
Application Serial No. 10/624,080

-2-


June 20, 2006

Please acknowledge receipt of the enclosed documents by stamping the enclosed postcard and returning same.

Respectfully submitted,

Amster, Rothstein & Ebenstein LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, NY 10016  
212-336-8000

Dated: New York, New York  
June 20, 2006

By:   
Elie Gendloff  
Registration No. 44,704



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/624,080

Confirmation No.: 5994

Applicants : Ganjam V. Kalpana


Filed : July 21, 2003

Art Unit : 1645

Examiner : Michelle S. Horning

Docket No. : 96700/819

Customer No. : 1912

"Express Mail" mailing label No.	EV 800501746 US
Date of Deposit:	June 20, 2006
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Elie H. Gendloff
Signature:	

REPLY TO ELECTION/RESTRICTION

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Reply is in response to the Election/Restriction dated May 24, 2006 in the above-identified patent application. Since this Reply is due June 24, 2006, it is timely filed.

Election/Restriction

In response to the restriction requirement imposed in the May 24, 2006 Office Action, Applicants elect Group I, claims 1-19, 24-25 and 31, drawn to peptides comprising an Rpt1 domain as well as related vectors and cells. This election is made without traverse.

In response to the species election requirement, Applicants elect Group b, directed to T cells.


Conclusion

It is believed that no fee is required with this Reply. If there are any unanticipated fees required to maintain pendency of this patent application, the PTO is hereby authorized to withdraw funds for those fees from Deposit Account 01-1785.

Respectfully submitted

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, NY 10016  
(212) 336-8000

Dated: New York, New York  
June 20, 2006

By:   
Elie H. Gendloff  
Registration No.: 44,704